Vargas-Uricoechea H, Aschner P. Comparative efficacy and safety of basal insulins: A review.
Diabetes Metab Syndr 2021;
15:102318. [PMID:
34695771 DOI:
10.1016/j.dsx.2021.102318]
[Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 08/09/2021] [Revised: 10/15/2021] [Accepted: 10/16/2021] [Indexed: 11/20/2022]
Abstract
BACKGROUND AND AIM
To provide an update on the usefulness of basal insulin in patients with type 2 diabetes mellitus.
METHODS
We conducted a literature search using PubMed and MEDLINE, BIOSIS, Scopus, EMBASE, ClinicalTrials.gov, Google Scholar, and Springer Online Archives Collection until June 2021.
RESULTS
All basal insulins are similar in efficacy, with only small differences among them in terms of the risk of hypoglycemia.
CONCLUSIONS
For type 2 diabetes mellitus, all basal insulins have a similar efficacy, with some advantage of Glar-300 and Deg-100 in reducing the risk of hypoglycemia compared to Glar-100.
Collapse